Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc (NQ: VRCA )

8.460 +0.030 (+0.36%)
Streaming Delayed Price Updated: 12:44 PM EDT, May 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verrica Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
53 Biggest Movers From Friday
Gainers Innate Pharma S.A. (NASDAQ: IPHA) shares surged 47.1% to settle at $6.15 on Friday after SVB Leerink upgraded the stock from Market Perform to Outperform. Vera... 
Via Benzinga
35 Stocks Moving In Friday's Mid-Day Session
Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 35% to $7.43. Cellect Biotechnology announced the first ApoGraft transplantation in a Leukemia patient in a... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
18 Key Biopharma Catalysts To Keep An Eye On In Q3
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the... 
Via Talk Markets
18 Key Biopharma Catalysts To Keep An Eye On In Q3
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne... 
Via Benzinga
Verrica's VP-102 Application Review for Molluscum Contagiosum Delayed till September
The FDA has extended the review period for the marketing application for Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) VP-102 to treat molluscum... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 14, 2021
Upgrades Canaccord Genuity upgraded the previous rating for Mogo Inc (NASDAQ:MOGO) from Hold to Speculative Buy. For the first quarter, Mogo had an EPS of $0.06, compared... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.